

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Health Protection Agency	08/08/2007

RECEIVING PARTY DATA

Name:	Syntaxin Limited
Street Address:	Porton Down
City:	Salisbury, Wiltshire
State/Country:	UNITED KINGDOM
Postal Code:	SP4 0JD

PROPERTY NUMBERS Total: 12

Property Type	Number
Patent Number:	6043042
Patent Number:	6337386
Patent Number:	5962637
Patent Number:	6632440
Application Number:	11062471
Application Number:	09937484
Application Number:	10129558
Application Number:	11327855
Application Number:	10130973
Application Number:	10478516
Application Number:	10521401
Application Number:	10571515

CORRESPONDENCE DATA

Fax Number: (202)326-0778

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

PATENT

500379518

REEL: 019984 FRAME: 0225

CH \$480.00 6043042

Phone: 202-326-0300
Email: pwine@merchantgould.com
Correspondent Name: Merchant & Gould P.C.
Address Line 1: P.O. Box 2903
Address Line 4: Minneapolis, MINNESOTA 55402-0903

ATTORNEY DOCKET NUMBER:

70085

NAME OF SUBMITTER:

Patricia Wine

Total Attachments: 25

source=70085 assignment docs#page1.tif
source=70085 assignment docs#page2.tif
source=70085 assignment docs#page3.tif
source=70085 assignment docs#page4.tif
source=70085 assignment docs#page5.tif
source=70085 assignment docs#page6.tif
source=70085 assignment docs#page7.tif
source=70085 assignment docs#page8.tif
source=70085 assignment docs#page9.tif
source=70085 assignment docs#page10.tif
source=70085 assignment docs#page11.tif
source=70085 assignment docs#page12.tif
source=70085 assignment docs#page13.tif
source=70085 assignment docs#page14.tif
source=70085 assignment docs#page15.tif
source=70085 assignment docs#page16.tif
source=70085 assignment docs#page17.tif
source=70085 assignment docs#page18.tif
source=70085 assignment docs#page19.tif
source=70085 assignment docs#page20.tif
source=70085 assignment docs#page21.tif
source=70085 assignment docs#page22.tif
source=70085 assignment docs#page23.tif
source=70085 assignment docs#page24.tif
source=70085 assignment docs#page25.tif



SAVILLE & CO

NOTARIES


One Carey Lane
London EC2V 8AE
Telephone: +44 (0)20 7920 0000
Facsimile: +44 (0)20 7920 0088
www.savillenotaries.com
mail@savillenotaries.com

Richard Saville
Ian Campbell
Sophie Jenkins
Nicholas Thompson



TO ALL TO WHOM THESE PRESENTS SHALL COME, I
IAN RODERICK CAMPBELL of the City of London
NOTARY PUBLIC by royal authority duly admitted and sworn
DO HEREBY CERTIFY that the photographic copy hereunto
annexed is a true copy of the original **intellectual property
assignment** and of the notarial certificate of RICHARD JOHN
SAVILLE, Notary Public practising at London, England,
attached thereto of which it purports to be a copy, I having
carefully collated and compared the said copy with the said
original and found the same to agree therewith.

IN FAITH AND TESTIMONY WHEREOF I the said notary
have subscribed my name and set and affixed my seal of office
at London aforesaid this fourteenth day of September two
thousand and seven.



SAVILLE & CO

NOTARIES

One Carey Lane
London EC2V 8AE
Telephone: +44 (0)20 7920 0000
Facsimile: +44 (0)20 7920 0088
www.savillenotaries.com
mail@savillenotaries.com

Richard Saville
Ian Campbell
Sophie Jenkins
Nicholas Thompson




TO ALL TO WHOM THESE PRESENTS SHALL COME, I RICHARD JOHN SAVILLE of the City of London NOTARY PUBLIC by royal authority duly admitted and sworn DO HEREBY CERTIFY the genuineness of the signatures of Professor PATRICIA ANN TROOP and JOHN MICHAEL HARKER subscribed to the **intellectual property assignment** hereunto annexed, such signatures being in the own, true, proper and respective handwriting of the said Professor Patricia Ann Troop and John Michael Harker, whose personal identity I attest, chief executive officer and secretary respectively of the **HEALTH PROTECTION AGENCY**, an independent agency established under the Health Protection Agency Act 2004, having its principal place of business at Porton Down, Salisbury, Wiltshire SP4 0JG, England and whose authority to execute the said intellectual property assignment, I the notary do also certify;

AND I DO FURTHER CERTIFY the genuineness of the signatures of CHARLES RICHARD PENN and PHILIP JAMES BOYD subscribed to the said annexed intellectual property assignment, such signatures being in the own, true, proper and respective handwriting of the said Charles Richard Penn and Philip James Boyd whose personal identity I attest, director and secretary respectively of **SYNTAXIN LIMITED**, a company duly organised and existing in accordance with the laws of England and Wales under company registration number 05480340 and having its registered office at Porton Down, Salisbury, Wiltshire SP30JD, England and whose authority to execute the said intellectual property assignment, I the notary do also certify;

AND I DO LASTLY CERTIFY that the said intellectual property assignment being so signed and delivered is duly executed as a deed in accordance with the provisions of English law.

IN FAITH AND TESTIMONY whereof I the said notary have subscribed my name and set and affixed my seal of office at London aforesaid this thirteenth day of September two thousand and seven.

RSaville



INTELLECTUAL PROPERTY ASSIGNMENT

THIS ASSIGNMENT is made the 8th day of August 2007

B E T W E E N:

- (1) **HEALTH PROTECTION AGENCY** whose principal place of business is at Porton Down, Salisbury, Wiltshire SP4 0JG ("Assignor"); and
- (2) **SYNTAXIN LIMITED** a company registered in England with company number 0580340 and having its registered office at Porton Down, Salisbury, Wiltshire SP4 0JD ("Assignee").

WHEREAS:

- (A) The parties entered into a licence agreement dated 10 November 2005 (the "Licence Agreement"). Pursuant to clause 2.1 of the Licence Agreement, the Assignor granted a licence to the Assignee to certain First Patent Rights and Know How (each as defined in the Licence Agreement) existing at the date of the Licence Agreement and as developed during the term of the Licence Agreement.
- (B) The Assignor is the sole registered proprietor of certain patents comprising the First Patent Rights, short particulars of which are set out in the Schedule hereto ("the Patents").
- (C) The Assignor is solely entitled to the benefit of certain patent applications comprising the First Patent Rights, short particulars of which are set out in the Schedule hereto ("the Applications").
- (D) The Assignor is the owner of the Know How as licensed by the Assignee pursuant to clause 2.1 of the Licence Agreement which is exclusively necessary to practice the First Patent Rights ("Know How").
- (E) The parties hereto have agreed that pursuant to clause 3.3.5 of the Licence Agreement, the Patents, the Applications and the Know How should be assigned by the Assignor to the Assignee on the terms and conditions of this Assignment.
- (F) The parties acknowledge that the License Agreement shall continue in full force and effect in respect of all the other intellectual property rights prescribed therein.

NOW THIS ASSIGNMENT WITNESSES as follows:

1. Interpretation

1.1 In this Assignment:

- 1.1.1 the headings to the clauses are for convenience only and shall not affect the interpretation or construction of this Assignment;
- 1.1.2 words importing the singular only shall include the plural and vice versa, words importing the masculine shall include the feminine and the neuter and words importing persons shall include bodies incorporated and unincorporated;

(22037634.06)

1.1.3 reference to any statute or statutory provision includes a reference to that statute or statutory provision as from time to time amended, extended or re-enacted; and

1.1.4 reference to the words 'includes' or 'including' shall be construed without limitation to the generality of the preceding words.

2. Assignment

In consideration of payment of £1, receipt of which is acknowledged by the Assignor, the Assignor with full title guarantee (other than with respect to infringement claims of third parties, in respect of which the Assignor shall give no guarantee to the Assignee) hereby assigns free of all encumbrances to the Assignee the Patents, the Applications, the right to apply for patent or similar protection in relation to the Applications in any part of the world (including the right to rely on any convention priority period), and the Know How, each as was in existence at the date of the Licence Agreement or as developed pursuant to the terms of the Licence Agreement (as applicable), and all property, right, title and interest therein together with the right to sue for and recover damages in respect of all infringements and threatened infringements of the Patents and the Applications, prior to the date hereof.

3. Required Assistance

3.1 Upon request by the Assignee and at the reasonable cost of the Assignor and without unreasonable delay, the Assignor shall:

3.1.1 assist with the prosecution of the Applications and execute all such documents and do all such acts as may be necessary for procuring the grant of patents pursuant to the Applications in the name of Assignee;

3.1.2 in the event that any proceedings are commenced relating to the validity, scope, inventorship and/or ownership of the Patents and/or any patent granted pursuant to the Applications or the Know How pursuant to which the Assignor has or can procure information which may assist in defending such challenge, the Assignor shall supply or procure the supply of such information;

3.1.3 at any time, execute any further documents and carry out any acts reasonably required to give effect to this Assignment.

4. Moral Rights

The Assignor waives all moral rights in respect of the intellectual property rights assigned to the Assignee under this Assignment which arise under the Copyright, Designs and Patents Act 1988 or any other similar or analogous rights throughout the world, to the fullest extent permissible by applicable law.

5. Further Assurance

The Assignor covenants with the Assignee that it will, at the direction of the Assignee and reasonable cost of the Assignor, do all such further acts and execute all such documents as may from time to time be necessary to vest in the Assignee to the extent required by this Assignment all Patents, Applications and Know-How and the Assignor hereby irrevocably

appoints the Assignee as its attorney to do all such further acts and execute such documents only as may be strictly necessary for such purpose.

6. **Non-Waiver**

6.1 Any failure or delay in enforcing an obligation or exercising a right under this Assignment does not amount to a waiver of that obligation or right.

6.2 The waiver of a breach of a term of this Assignment does not amount to a waiver of any other term.

6.3 A waiver of a breach of any of the terms of this Assignment will not prevent a party from subsequently requiring compliance with the waived obligation.

7. **Entire Agreement**

This Assignment, the Licence Agreement and the Subscription Agreement entered into between the parties and others on 10 November 2005, constitute the whole agreement and understanding between the Assignee and the Assignor with respect to the subject matter of this Assignment and supersede all prior agreements, negotiations and discussions between the parties relating to the subject matter of this Assignment.

8. **Law of Property (Miscellaneous Provisions) Act 1994**

All references to "full title guarantee" in this Assignment shall have the same meaning as set out in the Law of Property (Miscellaneous Provisions) Act 1994.

9. **Governing Law**

This Assignment shall be governed by English law and the parties hereto submit to the exclusive jurisdiction of the English Courts.

10. **Third Party Rights**

No third party shall have the right to enforce any provision of this Assignment by virtue of the Contracts (Rights of Third Parties) Act 1999.

11 **Counterparts**

This Assignment may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF the parties hereto have executed this Assignment as a deed on the day and year first above written

EXECUTED AS A DEED
for and on behalf
of the Health Protection Agency
acting by




Signature of director

Pa Troop

Name of director (print)

)
)
)



Signature of director / company secretary
(Please delete as applicable)

Jm Haked

Name of director/company secretary (print)

EXECUTED AS A DEED
for and on behalf
of Syntaxin Limited
acting by

Signature of director

Name of director (print)

)
)
)

Signature of director / company secretary
(Please delete as applicable)

Name of director/company secretary (print)

IN WITNESS WHEREOF the parties hereto have executed this Assignment as a deed on the day and year first above written

EXECUTED AS A DEED

for and on behalf

of the Health Protection Agency

acting by

)

)

)

Signature of director

Signature of director / company secretary
(Please delete as applicable)

Name of director (print)

Name of director/company secretary (print)

EXECUTED AS A DEED

for and on behalf


of Syntaxin Limited

acting by


)

)

)



Signature of director



Signature of ~~director~~ / company secretary
(Please delete as applicable)



Name of director (print)



Name of ~~director~~ / company secretary (print)

Name of ~~director~~ / company secretary (print)

SCHEDULE
PATENTS AND APPLICATIONS

M&S Ref.	Country	Title	Application Date	Application No.	Registration No.	Case Status
P17805AT- EPC-PCT	Austria	Toxin assay	02/06/1995	95921033.7	0763131	Granted
P17805AU-PCT	Australia	Toxin assay	02/06/1995	26240/95	687564	Granted
P17805BE- EPC-PCT	Belgium	Toxin assay	02/06/1995	95921033.7	0763131	Granted
P17805CA-PCT	Canada	Toxin assay	02/06/1995	2191895		Pending
P17805CH- EPC-PCT	Switzerland & Liechtenstein	Toxin assay	02/06/1995	95921033.7	0763131	Granted
P17805DE- EPC-PCT	Germany	Toxin assay	02/06/1995	95921033.7	69511693.2	Granted
P17805DK- EPC-PCT	Denmark	Toxin assay	02/06/1995	95921033.7	0763131	Granted
P17805EP-PCT	European Patent Office	Toxin assay	02/06/1995	95921033.7	0763131	Granted
P17805FR- EPC-PCT	France	Toxin assay	02/06/1995	95921033.7	0763131	Granted
P17805GB	United Kingdom	Toxin assay	03/06/1994	9411138.2		Priority Only
P17805GB- EPC-PCT	United Kingdom	Assay of tetanus - and botulinum toxins	02/06/1995	0763131	0763131	Granted
P17805IT-EPC- PCT	Italy	Toxin assay	02/06/1995	95921033.7	0763131	Granted
P17805JP-PCT	Japan	Toxin assay	02/06/1995	500544/1995		Pending
P17805NL- EPC-PCT	Netherlands	Toxin assay	02/06/1995	95921033.7	0763131	Granted
P17805SE- EPC-PCT	Sweden	Toxin assay	02/06/1995	95921033.7	0763131	Granted

(22037634.06)

P17805US-D1-PCT	United States of America	Toxin assay	02/06/1995	09/015960	6043042	Granted
P17805US-D2	United States of America	Toxin assay	02/06/1995	09/534572	6337386	Granted
P17805US-PCT	United States of America	Toxin assay	02/06/1995	08/760001	5962637	Granted
P17805WO	PCT	Toxin assay	02/06/1995	PCT/GB95/01279		See National Phase

P20853AT- EPC-PCT	Austria	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853AU-PCT	Australia	Treatment of mucus hypersecretion	25/08/1999	55250/99	756063	Granted
P20853BE- EPC-PCT	Belgium	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853CA-PCT	Canada	Treatment of mucus hypersecretion	25/08/1999	2341429		Pending
P20853CHL- EPC-PCT	Switzerland & Liechtenstein	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853CY- EPC-PCT	Cyprus	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853DE- EPC-PCT	Germany	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853DK- EPC-PCT	Denmark	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853EP-PCT	European Patent Office	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853ES- EPC-PCT	Spain	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853FI-EPC- PCT	Finland	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853FR- EPC-PCT	France	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853GB	United Kingdom	Treatment of mucus hypersecretion	25/08/1998	9818548.1		Priority Only
P20853GB- EPC-PCT	United Kingdom	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853GR- EPC-PCT	Greece	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853IE-EPC- PCT	Ireland	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853IT-EPC- PCT	Italy	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853JP-PCT	Japan	Treatment of mucus hypersecretion	25/08/1999	565918/2000		Pending

(22037634.06)

P20853LU- EPC-PCT	Luxembourg	hypersecretion Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853MC- EPC-PCT	Monaco	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853NL- EPC-PCT	Netherlands	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853PT- EPC-PCT	Portugal	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted

P20853SE-EPC-PCT	Sweden	Treatment of mucus hypersecretion	25/08/1999	99941754.6	1107794	Granted
P20853US-C1-PCT	United States of America	Treatment of mucus hypersecretion	25/08/1999	10/633698		Abandoned
P20853US-C2-PCT	United States of America	Treatment of mucus hypersecretion	25/08/1999	11/518213		Awaiting filing receipt
P20853US-C3-PCT	United States of America	Treatment of mucus hypersecretion [Integrin and EGF constructs]	25/08/1999			Not yet Filed
P20853US-PCT	United States of America	Treatment of mucus hypersecretion	25/08/1999	09/763669	6632440	Granted
P20853WO	PCT	Treatment of mucus hypersecretion	25/08/1999	PCT/GB99/02806		See National Phase

P20994AU-PCT	Australia	Delivery of superoxide dismutase to neuronal cells	05/11/1999	10594/00	754883	Granted
P20994CA-PCT	Canada	Delivery of superoxide dismutase to neuronal cells	05/11/1999	2349496		Pending
P20994EP-PCT	European Patent Office	Delivery of superoxide dismutase to neuronal cells	05/11/1999	99954163.4		Pending
P20994GB	United Kingdom	Delivery of superoxide dismutase to neuronal cells	05/11/1998	9824282.9		Priority Only
P20994JP-PCT	Japan	Delivery of superoxide dismutase to neuronal cells	05/11/1999	581208/2000		Pending
P20994US-C1-PCT	United States of America	Delivery of superoxide dismutase to neuronal cells	05/11/1999	11/062471		Application filed
P20994US-PCT	United States of America	Delivery of superoxide dismutase to neuronal cells	05/11/1999	09/831050		Abandoned
P20994WO	PCT	Delivery of superoxide dismutase to neuronal cells	05/11/1999	PCT/GB99/03699		See National Phase

P21034AU-PCT	Australia	Use of a lectin or conjugates for modulation of C-fibre activity	31/03/2000	35690/00	776281	Granted
P21034CA-PCT	Canada	Modulation of C-Fibre activity	31/03/2000	2368641		Pending
P21034EP-PCT	European Patent Office	Modulation of C-Fibre activity	31/03/2000	00914295.1		Pending
P21034GB	United Kingdom	Modulation of C-Fibre activity	31/03/1999	9907429.6		Priority Only
P21034JP-PCT	Japan	Modulation of C-Fibre activity	31/03/2000	607647/2000		Pending
P21034US-PCT	United States of America	Modulation of C-Fibre activity	31/03/2000	09/937484		Allowed
P21034WO	PCT	Modulation of C-Fibre activity	31/03/2000	PCT/GB00/01247		See National Phase

P21250AU-PCT	Australia	Use of lytic toxins and toxin conjugates	13/11/2000	12906/01	781677	Granted
P21250CA-PCT	Canada	Use of Lytic Toxins and Toxin Conjugates	13/11/2000	2388643		Pending
P21250EP-PCT	European Patent Office	Use of Lytic Toxins and Toxin Conjugates	13/11/2000	00974690.0		Pending
P21250GB	United Kingdom	Use of Lytic Toxins and Toxin Conjugates	12/11/1999	9926875.7		Priority Only
P21250JP-PCT	Japan	Use of Lytic Toxins and Toxin Conjugates	13/11/2000	536202/2001		Pending
P21250US-C1-PCT	United States of America	Use of Lytic Toxins and Toxin Conjugates [CDT per se claims]	13/11/2000			Not yet Filed
P21250US-PCT	United States of America	Use of Lytic Toxins and Toxin Conjugates	13/11/2000	10/129558		Pending
P21250WO	PCT	Use of Lytic Toxins and Toxin Conjugates	13/11/2000	PCT/GB00/04329		See National Phase

P21755AU-D1-PCT	Australia	Inhibition of secretion from non-neuronal cells	25/09/2000	2005227383		Pending
P21755AU-PCT	Australia	Inhibition of secretion from non-neuronal cells	25/09/2000	74365/00	782457	Granted
P21755CA-PCT	Canada	Inhibition of secretion from non-neuronal cells	25/09/2000	2383470		Pending
P21755EP-PCT	European Patent Office	Inhibition of secretion from non-neuronal cells	25/09/2000	00962721.7		Pending
P21755GB	United Kingdom	Inhibition of secretion from non-neuronal cells	23/09/1999	9922554.2		Priority Only
P21755GB-01	United Kingdom	Inhibition of secretion from non-neuronal cells	23/09/1999	9922558.3		Priority Only
P21755JP-PCT	Japan	Inhibition of secretion from non-neuronal cells	25/09/2000	524636/2001		Pending
P21755US-01-PCT	United States of America	Inhibition of secretion from non-neuronal cells	25/09/2000	10/088665		Abandoned

P21755US-C1-PCT	United States of America	Inhibition of secretion from non-neuronal cells	25/09/2000	11/327855	Pending
P21755WO	PCT	Inhibition of secretion from non-neuronal cells	25/09/2000	PCT/GB00/03669	See National Phase
P21755WO-01	PCT	Inhibition of secretion from non-neuronal cells	25/09/2000	PCT/GB00/03681	See National Phase

P21812AT- EPC-PCT	Austria	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812AU-PCT	Australia	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	17193/01	768529	Granted
P21812BE- EPC-PCT	Belgium	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812CA-PCT	Canada	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	2392202		Pending
P21812CH- EPC-PCT	Switzerland & Liechtenstein	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812CY- EPC-PCT	Cyprus	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted

P21812DE- EPC-PCT	Germany	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	00979809.1	1234043	Granted
P21812DK- EPC-PCT	Denmark	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812EP-PCT	European Patent Office	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	00979809.1	1234043	Granted
P21812ES- EPC-PCT	Spain	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812FI-EPC- PCT	Finland	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812FR- EPC-PCT	France	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	00979809.1	1234043	Granted

P21812GB	United Kingdom	Constructs for delivery of therapeutic agents to neuronal cells	02/12/1999	9928530.6		Priority Only
P21812GB-01	United Kingdom	Constructs for delivery of therapeutic agents to neuronal cells	07/04/2000	0008658.7		Priority Only
P21812GB-EPC-PCT	United Kingdom	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812GR-EPC-PCT	Greece	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812IE-EPC-PCT	Ireland	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812IT-EPC-PCT	Italy	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted

P21812JP-PCT	Japan	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	558083/2001		Pending
P21812LU-EPC-PCT	Luxembourg	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812MC-EPC-PCT	Monaco	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812NL-EPC-PCT	Netherlands	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812PT-EPC-PCT	Portugal	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812SE-EPC-PCT	Sweden	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted

P21812TR- EPC-PCT	Turkey	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	1234043	1234043	Granted
P21812US-C1- PCT	United States of America	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000			Not yet Filed
P21812US-PCT	United States of America	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	10/130973		Pending
P21812WO	PCT	Constructs for delivery of therapeutic agents to neuronal cells	04/12/2000	PCT/GB00/04644		See National Phase

P23433AU-PCT	Australia	Pharmaceutical use of secreted bacterial effector proteins	21/05/2002	2002256803	2002256803	Pending
P23433CA-PCT	Canada	Pharmaceutical use of secreted bacterial effector proteins	21/05/2002	2448963		Pending
P23433CN-PCT	China	Pharmaceutical use of secreted bacterial effector proteins	21/05/2002	02810505.2		Pending
P23433EP-PCT	European Patent Office	Pharmaceutical use of secreted bacterial effector proteins	21/05/2002	02726319.3		Pending
P23433GB	United Kingdom	Pharmaceutical use of secreted bacterial effector proteins	24/05/2001	0112687.9		Priority Only
P23433IN-PCT	India	Pharmaceutical use of secreted bacterial effector proteins	21/05/2002	1388/KOLNP/2003		Pending
P23433JP-PCT	Japan	Pharmaceutical use of secreted bacterial effector proteins	21/05/2002	592975/2002		Pending
P23433US-PCT	United States of America	Pharmaceutical use of secreted bacterial effector proteins	21/05/2002	10/478516		Pending

P23433WO	PCT	Pharmaceutical use of secreted bacterial effector proteins	21/05/2002	PCT/GB02/02384	See National Phase
P24346AU-PCT	Australia	Targeted agents for nerve regeneration	15/07/2003	2003254463	Pending
P24346CA-PCT	Canada	Targeted agents for nerve regeneration	15/07/2003	2492806	Pending
P24346EP-PCT	European Patent Office	Targeted agents for nerve regeneration	15/07/2003	03765155.1	Pending
P24346GB	United Kingdom	Targeted agents for nerve regeneration	19/07/2002	0216865.6	Priority Only
P24346JP-PCT	Japan	Targeted agents for nerve regeneration	15/07/2003	522304/2004	Pending
P24346US-PCT	United States of America	Targeted agents for nerve regeneration	15/07/2003	10/521401	Pending
P24346WO	PCT	Targeted agents for nerve regeneration	15/07/2003	PCT/GB03/03082	See National Phase

P24533AU-PCT	Australia	Re-targeted toxin conjugates	13/09/2004	200426979	Pending
P24533CA-PCT	Canada	Re-targeted toxin conjugates	13/09/2004	2538619	Pending
P24533EP-PCT	European Patent Office	Re-targeted toxin conjugates	13/09/2004	04768450.1	Pending
P24533GB	United Kingdom	Re-targeted toxin conjugates	11/09/2003	0321344.4	Priority Only
P24533JP-PCT	Japan	Re-targeted toxin conjugates	13/09/2004	2006-525899	Pending
P24533US-PCT	United States of America	Re-targeted toxin conjugates	13/09/2004	10/571515	Pending
P24533WO	PCT	Re-targeted toxin conjugates	13/09/2004	PCT/GB04/03904	Lapsed
P26513GB	United Kingdom	Fusion Proteins	01/12/2004	0426399.2	Priority Only
P26513WO	PCT	Fusion Proteins	01/12/2005	PCT/GB05/04592	Abandoned
P26885GB	United Kingdom	Fusion proteins	01/12/2004	0426394.3	Priority Only
P27134GB	United Kingdom	Fusion proteins	01/12/2004	0426397.6	Priority Only
P27134WO	PCT	Fusion proteins	01/12/2005	PCT/GB05/04606	Pending